Inicio › Mieloma múltiple › Alabama
Ensayos clínicos de Mieloma múltiple en Alabama
22 estudios sobre Mieloma múltiple buscan participantes en Alabama.
Ciudades en Alabama
Texto oficial del estudio (inglés)
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
- University of Alabama At Birmingham Hospital, Birmingham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT04973605A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
- Alabama Oncology, Birmingham
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT07518186A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama Birmingham, Birmingham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT04634552A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham Hospital, Birmingham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 23 sept 2026 · NCT07116616TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
- University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham
ReclutandoFase 2
Edades de 12 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT02693535A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT06615479Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT06297226A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
- Infirmary Health - Diagnostic & Medical Clinic (DMC), Mobile
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 sept 2026 · NCT06980480A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 2 sept 2026 · NCT06988488MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
- Infirmary Cancer Care, Mobile
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 24 ago 2026 · NCT06152575AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Research Site, Birmingham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 ago 2026 · NCT05850234A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
- Clearview Cancer Institute, Huntsville
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 6 ago 2026 · NCT07284758A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 16 jul 2026 · NCT06121843Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 2
Edades de 19 en adelante · Todos los sexos · Actualizado el 4 jun 2026 · NCT06974786A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
- GSK Investigational Site, Mobile
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 abr 2026 · NCT06679101A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 18 mar 2026 · NCT06153251Study of BMS-986453 in Newly Diagnosed Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 1
Edades de 19 en adelante · Todos los sexos · Actualizado el 13 feb 2026 · NCT07333261Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 31 dic 2025 · NCT04991103Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
- Kirklin Clinic of UAB Hospital, Birmingham
Reclutando
Edades de 60 en adelante · Todos los sexos · Actualizado el 24 dic 2025 · NCT05642884Cancer and Aging Resilience Evaluation in Older Adults With Hematologic Malignancies: The CARE-Heme Registry
- Kirklin Clinic of UAB Hospital, Birmingham
ReclutandoEstudio observacional
Edades de 50 en adelante · Todos los sexos · Actualizado el 8 dic 2025 · NCT05556928CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
- University of Alabama at Birmingham, Birmingham
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2025 · NCT05722418A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or Refractory Multiple Myeloma
- UAB Comprehensive Cancer Center, Birmingham
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 5 sept 2025 · NCT05372354De ClinicalTrials.gov, datos obtenidos el 30 sept 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.